21世纪经济报道记者季媛媛上海报道2023年10月,诺和诺德以高达13亿美元的价格收购亨利医药(KBP Biosciences)的核心资产Ocedurenone,引发行业广泛关注。该药物是一款第三代非甾体盐皮质激素受体拮抗剂(MRA),旨在通过控制高血压延缓慢性肾病(CKD)进展。当时,诺和诺德高管Camilla Sylvest指出,Ocedurenone将强化公司在心血管和肾病领域的产品线,并...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.